Saudi oncology society and Saudi urology association combined clinical management guidelines for renal cell carcinoma
Renal cancer represents the third common genitourinary cancer in Saudi Arabia after urinary bladder and prostate. [1] It accounts for 3.6% of all male cancers and 2.2% of all female cancers. In 2010, a total of 167 cases where diagnosed in males and 117 cases in females. The Age standardized rate in males was 2.9/100,000 and in females was 2/100,000 populations.
All cases of renal cell carcinoma (RCC) should preferably seen or discussed in a multidisciplinary forum 1. Pretreatment evaluation:
1. 2. Staging: [2] The American Joint Commission on cancer staging tumor node metastasis 7 th edition will be adopted. 3. Risk stratification for metastatic RCC:
The Memorial Sloan Kettering Cancer Center (MSKCC) risk classification for metastatic disease will be used: [3] IIIa, b, c) 4.4.1. The recommended treatment is radical nephrectomy with complete excision of all venous thrombus in the renal vein, inferior vena cava, and right atrium (EL-2). [15, 16] 4.4.2. These surgeries should only be performed in a tertiary care centers with the availability of cardiac, vascular or hepatic surgeon depending on the case (EL-2). [29, 30] 4.5. Excision of the ipsilateral adrenal gland 4.5.1. Ipsilateral excision of the adrenal gland during radical nephrectomy is indicated in upper pole tumors or in the presence of a concurrent radiologicaly detectable adrenal gland lesion (s) (EL-2). [31] [32] [33] [34] 4.6. Lymphnode dissection 4.6.1. Resection of the regional lymphnodes (within Gerota's fascia) is an integral part of radical nephrectomy 4.6.2. Resection of the nonregional lymphnodes provides no therapeutic advantages and it is used for staging purposes (EL-1). [35] 4.7. When doing partial nephrectomy the surgeon should aim to obtain adequate surgical margin and avoid tumor inoculation. [36] [37] [38] 4.8. Metastatic/advanced disease: Several scenarios could be faced in patients with metastatic disease. Accordingly the following should be considered: 4.8.1. Potentially resectable primary with solitary metastasis or multiple resectable lung metastasis: Those patients should undergo primary nephrectomy and resection of the metastatic lesion/s (EL-2). [39] Following complete resection no further therapy or "adjuvant therapy" is indicated (EL-3). 4.8.2. Potentially resectable primary and multiple metastasis: Those patients should undergo resection of the primary tumor if in good performance status (EL-1), [40, 41] then should start systemic therapy according to the following guidelines: 4.8.2.1. Clear cell histology, good and intermediate risk:
Options of therapy include systemic therapy with either sunitinib [42] (EL-1), Bevacizumab and interferon α-2a [43, 44] or pazopanib [45] (EL-1).
Clear cell histology with poor risk:
Temsirolimus is the preferred treatment. [46] (EL-1) [47] sunitinib [48] (EL-2), or sorafenib [48, 49] (EL-2). Medullary and collecting duct carcinoma should be treated with platinum based chemotherapy [50, 51] [55, 56] or axitinib [57] (EL-1).
